<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01070927</url>
  </required_header>
  <id_info>
    <org_study_id>NP22383</org_study_id>
    <secondary_id>2008-006384-37</secondary_id>
    <nct_id>NCT01070927</nct_id>
  </id_info>
  <brief_title>An Exploratory Study of RO4929097 in Patients With Recurrent or Refractory Non-Small Cell Lung Cancer</brief_title>
  <official_title>An Exploratory Study on Anti-tumour Activity of Orally Administered RO4929097, a Gamma-secretase Inhibitor, as a Single Agent in Patients With Recurrent or Refractory Non-Small Cell Lung Cancer (NSCLC).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This study will evaluate the anti-tumour activity, safety and tolerability of RO4929097 as
      monotherapy in patients with recurrent or refractory non-small cell lung cancer. Patients
      will receive oral doses of RO4929097 of 80mg (cohort 1) or recommended Phase II dose (cohort
      2) on a 3 days on 4 days off schedule. Anticipated time on study treatment is until disease
      progression or unacceptable toxicity. Target sample size is &lt;50.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumour blood flow and tumour metabolic response rate</measure>
    <time_frame>PET and CT assessments on day 4 (cycle 1) and day 16 (cycles 1 and 2)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile and pharmacodynamic parameters (e.g. changes in circulating endothelial and hematopoietic precursors)</measure>
    <time_frame>pharmacokinetics: cycle 1 on days 1, 2, 4, 10, 11, 16; cycle 2 on days 1, 2, 16\npharmacodynamics: cycle 1 on days 1, 2, 4, 11, 16; cycle 2 on days 1, 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumour response according to RECIST criteria</measure>
    <time_frame>assessments once every 2nd cycle on day 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability: AEs, laboratory parameters</measure>
    <time_frame>throughout study, laboratory assessments on days 1, 8 and 15 of each cycle</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Non-Squamous Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO4929097</intervention_name>
    <description>80mg po daily, 3 days on 4 days off schedule</description>
    <arm_group_label>cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO4929097</intervention_name>
    <description>recommended phaseII dose, orally once daily, 3 days on 4 days off schedule</description>
    <arm_group_label>cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patients, &gt;/= 18 years of age

          -  stage IIIB/IV recurrent or refractory non-small cell lung cancer

          -  at most 2 lines of prior therapy in the metastatic setting (first line: platinum
             containing regimen and bevacizumab; second line: EGFR-targeted therapy)

          -  ECOG performance status 0-2

          -  adequate liver, renal and bone marrow function

        Exclusion Criteria:

          -  prior chemotherapy or radiotherapy &lt;/= 4 weeks before first dose of study drug

          -  history of other malignancy within the past 2 years, except for basal cell skin
             carcinoma or in situ cervical carcinoma

          -  history of CNS metastases or leptomeningeal metastases, except for clinically stable
             disease

          -  serious cardiovascular illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <zip>1007 MB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2010</study_first_submitted>
  <study_first_submitted_qc>February 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2010</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

